Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis

Oncologist

Volumn 18, Issue 4, 2013, Pages 353-361

  Valachis, Antonis ^a,b   Polyzos, Nikolaos P ^c,d   Coleman, Robert E ^e   Gnant, Michael ^f   Eidtmann, Holger ^g   Brufsky, Adam M ^h   Rebecca, Aft ⁱ   Tevaarwerk, Amye J ^j   Swenson, Karen ^k   Lind, Pehr ^a,l   Mauri, Davide ^d  

^a Hospital of Eskilstuna   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^d Panhellenic Association for Continual Medical Research PACMeR   (Greece)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF WISCONSIN   (United States)

^k PARK NICOLLET INSTITUTE   (United States)

^l KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Adjuvant; Bisphosphonates; Breast cancer; Zoledronic acid

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FRACTURE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; NEOPLASM STAGING; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84877069785     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0261     Document Type: Article

References (45)

1. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97:2692-2696.
2. Jansen JP, Bergman GJ, Huels J et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: A network meta-analysis. Semin Arthritis Rheum 2011;40:275-284.e1-e2.
3. Machado M, Cruz LS, Tannus G et al. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials. Clin Ther 2009;31:962-979.
4. Daubiné F, Le Gall C, Gasser J et al. Antitumor effects of clinical dosingregimensofbisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-330.
5. van der Pluijm G, Vloedgraven H, van Beek E et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
6. Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonatesinduceapoptosis inhumanbreast cancer cell lines. Br J Cancer 2000;82:1459-1468.
7. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone- stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62: 6538-6544.
8. Mauri D, Valachis A, Polyzos NP et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010;8:279-286.
9. Valachis A, Polyzos NP, Georgoulias V et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol 2010;117:139-145.
10. Brufsky AM, Bosserman LD, Caradonna RR et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
11. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al.; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early- stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-849.
12. Kim JE, Ahn JH, Jung KH et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06- 01). Breast Cancer Res Treat 2011;125:99-106.
13. Hershman DL, McMahon DJ, Crew KD et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 2010;95:559-566.
14. Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38:617-627.
15. Russell RGG. Determinants of structure-function relationships among bisphosphonates. Bone 2007;40:S21-S25.
16. Verdijk R, Franke HR, Wolbers F et al. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007;246:308-312.
17. Higgins JP, Altman DG, Gtzsche PC et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
18. Mauri D, Valachis A, Polyzos IP et al. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: A meta-analysis. Breast Cancer Res Treat 2009;116:433-439.
19. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
20. Coleman RE, Marshall H, Cameron D et al.; AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365: 1396-1405.
21. Gnant M, Mlineritsch B, Stoeger H et al.; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early- stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12:631-641.
22. Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010;21:2188-2194.
23. Brufsky AM, Harker WG, Beck JT et al. Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012;118:1192-1201.
24. Hines SL, Mincey B, Dentchev T et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen- N03CC. Breast Cancer Res Treat 2009;117:603-609.
25. Coleman R, Bundred N, de Boer R et al. Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Cancer Res 2009; 69(24 suppl):4082.
26. Rossi E, Morabito A, Di Rella F et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: The HOBOE trial. J Clin Oncol 2009;27:3192-3197.
27. Takahashi S, Iwase T, Kohno N et al. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 2012;133:685-693.
28. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-428.
29. Safra T, Bernstein-Molho R, Greenberg J et al. Theprotective effect of zoledronic acidonboneloss in postmenopausalwomenwith early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial. Oncology 2011;81:298-305.
30. Hadji P, Kauka A, Bauer T et al. Influence of zoledronic acid on BMD in premenopausal women with breast cancer and neoadjuvant or adjuvant chemotherapy and/or endocrine treatment- the ProBonestudies. Cancer Res 2011;71(24 suppl):P2-19-03.
31. Leal T, Tevaarwerk A, Love R et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clin Breast Cancer 2010;10:471-476.
32. Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 2009;7:101-107.
33. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res 2011;71(24 suppl):S1-S2.
34. de Boer R, Bundred N, Eidtmann H et al. Longterm survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-Year follow-up of ZO-FAST. Cancer Res 2011;71(24 suppl):S1-S3.
35. Gallo M, De Luca A, Lamura L et al. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: Implications for adjuvant therapy of breast cancer. Ann Oncol 2012; 23:597-604.
36. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-521.
37. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
38. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
39. Morgan GJ, Davies FE, Gregory WM et al.; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 2010;376:1989-1999.
40. Yan T, Yin W, Zhou Q et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. Eur J Cancer 2012;48:187-195.
41. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: One answer is not always enough. Lancet 1998;351:123-127.
42. Jones AP, Riley RD, Williamson PR et al. Metaanalysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials 2009;6:16-27.
43. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007; 7:5.
44. Polyzos NP, Polyzos IP, Zavos A et al. Obstetric outcomes after treatment of periodontal disease during pregnancy: Systematic review and metaanalysis. BMJ 2010;341:c7017.
45. Balk EM, Bonis PA, Moskowitz H et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002;287:2973-2982.